PfSPZ疫苗在马里健康成人和计划妊娠女性中预防疟疾的安全性及有效性:两项随机双盲安慰剂对照1期和2期试验
在马里开展的两项随机双盲安慰剂对照试验中,健康成人和计划妊娠女性分别接种9×10^5或1.8×10^6 PfSPZ疫苗或生理盐水安慰剂。MLSPZV3中9×10^5剂量4周和16周方案未显示预防寄生虫血症的疫苗效力;MLSPZV4中两种剂量均显示对寄生虫血症和临床疟疾的显著效力,对妊娠期疟疾也有效力。疫苗安全且耐受性良好。
要点
- MLSPZV4中9×10^5剂量第1年对寄生虫血症效力41%,第2年61%。
- MLSPZV4中1.8×10^6剂量第1年对寄生虫血症效力54%,第2年45%。
- 接种前未给予 presumptive 抗疟治疗的MLSPZV3未显示疫苗效力。
核心结论
- PfSPZ疫苗在马里成人中安全且耐受性良好。
- 按4周方案接种9×10^5和1.8×10^6剂量(首剂前含 presumptive 抗疟治疗)在育龄女性中对寄生虫血症和临床疟疾显示显著效力,并持续两个疟疾传播季,对妊娠期疟疾也有效力。
- 首剂前未给予 presumptive 抗疟治疗的PfSPZ疫苗未显示效力。
研究设计与样本
- 两项随机双盲安慰剂对照试验(1期MLSPZV3和2期MLSPZV4)在马里一家临床研究中心开展。
- MLSPZV3纳入18-35岁成人,按村庄分层区组随机2:1分配接种9×10^5 PfSPZ疫苗或生理盐水安慰剂,方案为第0、1、4周或第0、8、16周三剂,约1年后加强一剂。
- MLSPZV4纳入18-38岁计划入组后一年内妊娠的非妊娠女性,首剂前2周接受 presumptive 蒿甲醚-苯芴醇每日两次共3天,按区组随机1:1:1分配接种9×10^5或1.8×10^6 PfSPZ疫苗或生理盐水安慰剂,均按第0、1、4周三剂方案。
- 两项研究均在第三剂前2周给予蒿甲醚-苯芴醇,MLSPZV3还在第四剂(加强剂)前2周给予。
- 主要结局为每剂后7天内PfSPZ疫苗安全性和耐受性(as-treated人群);次要结局为第三剂至传播季结束对恶性疟原虫寄生虫血症的疫苗效力(modified intention-to-treat人群)。
主要发现
- MLSPZV3中9×10^5剂量4周方案对寄生虫血症的疫苗效力第1年为27%(95%CI -18至55),第2年为42%(95%CI -5至68);16周方案第1年为16%(95%CI -34至48),第2年为-14%(95%CI -95至33)。
- MLSPZV4中9×10^5剂量对寄生虫血症的疫苗效力第1年为41%(95%CI 15至59;p=0.0069),第2年为61%(95%CI 36至77;p=0.0011);1.8×10^6剂量第1年为54%(95%CI 34至69;p<0.0001),第2年为45%(95%CI 13至65;p=0.029)。
- MLSPZV4中9×10^5剂量对临床疟疾的疫苗效力第1年为47%(95%CI 20至65;p=0.0045),第2年为56%(95%CI 22至75;p=0.0081);1.8×10^6剂量第1年为48%(95%CI 22至65;p=0.0013),第2年为40%(95%CI 2至64;p=0.069)。
- 2年随访中首次妊娠期间对受孕后恶性疟原虫寄生虫血症的疫苗效力:9×10^5组为57%(95%CI 14至78;p=0.017),1.8×10^6组为49%(95%CI 3至73;p=0.042)。
- 第三剂后24周内妊娠的55名女性中,对寄生虫血症的疫苗效力9×10^5组为65%(95%CI 23至84;p=0.0088),1.8×10^6组为86%(95%CI 64至94;p<0.0001)。
关键数值与推荐
- MLSPZV3中16周方案9×10^5组69人中66人(96%)、4周方案9×10^5组70人中68人(97%)、生理盐水组71人中70人(99%)完成第1年全部三剂。
- MLSPZV4中首剂前2周接受 presumptive 蒿甲醚-苯芴醇每日两次共3天,随机分配300名女性每组100人接受首剂。
- MLSPZV4中早期流产为最常见严重不良事件,各组发生率相近:9×10^5组54人中8人(15%),1.8×10^6组58人中12人(21%),生理盐水组43人中5人(12%)。
- MLSPZV4中1.8×10^6组末次疫苗剂量后425天发生1例无关孕产妇死亡,死于分娩后不久的腹膜炎。
- MLSPZV3中发生2例无关严重不良事件:9×10^5组1人阑尾炎,生理盐水组1人死于交通事故。
临床怎么用
- 原文未据此给出推荐。
- 作者指出,按4周方案接种9×10^5和1.8×10^6剂量(首剂前含 presumptive 抗疟治疗)在育龄女性中对寄生虫血症和临床疟疾显示显著效力。
- 作者指出,首剂前未给予 presumptive 抗疟治疗的PfSPZ疫苗未显示效力。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Plasmodium falciparum parasitaemia during pregnancy causes maternal, fetal, and infant mortality. Poor pregnancy outcomes are related to blood-stage parasite sequestration and the ensuing inflammatory response in the placenta, which decreases over successive pregnancies. A radiation-attenuated, non-replicating, whole-organism vaccine based on P falciparum sporozoites (PfSPZ Vaccine) has shown efficacy at preventing infection in African adults. Here, we aimed to examine vaccine safety and efficacy of the PfSPZ Vaccine in adults and women who anticipated conception. METHODS: Two randomised, double-blind, placebo-controlled trials (phase 1 MLSPZV3 and phase 2 MLSPZV4) were conducted at a clinical research centre in Mali. MLSPZV3 included adults aged 18-35 years and MLSPZV4 included non-pregnant women aged 18-38 years who anticipated conception within a year of enrolment. In MLSPZV3, participants were stratified by village and randomly assigned (2:1) using block randomisation to receive three doses of 9 × 105 PfSPZ Vaccine or saline placebo at weeks 0, 1, and 4 (4-week schedule) or at weeks 0, 8, and 16 (16-week schedule) and a booster dose around 1 year later. In MLSPZV4, women received presumptive artemether-lumefantrine twice per day for 3 days 2 weeks before dose one and were randomly assigned (1:1:1) using block randomisation to receive three doses of 9 × 105 or 1·8 × 106 PfSPZ Vaccine or saline placebo all administered at weeks 0, 1, and 4 (4-week schedule). Participants in both studies received artemether-lumefantrine 2 weeks before dose three and additionally 2 weeks before dose four (booster dose) in MLSPZV3. Investigators and participants were masked to group assignment. The primary outcome, assessed in the as-treated population, was PfSPZ Vaccine safety and tolerability within 7 days after each dose. The secondary outcome, assessed in the modified intention-to-treat population, was vaccine efficacy against P falciparum parasitaemia (defined as the time-to-first positive blood smear) from dose three until the end of transmission season. In exploratory analyses, MLSPZV4 evaluated incidence of maternal obstetric and neonatal outcomes as safety outcomes, and vaccine efficacy against P falciparum parasitaemia during pregnancy (defined as time-to-first positive blood smear post-conception). In MLSPZV4, women were followed at least once a month with human chorionic gonadotropin testing, and those who became pregnant received standard of care (including intermittent presumptive sulfadoxine-pyrimethamine antimalarial drugs after the first trimester) during routine antenatal visits. These studies are registered with ClinicalTrials.gov, NCT03510481 and NCT03989102. FINDINGS: Participants were enrolled for vaccination during the onset of malaria seasons for two sequential studies conducted from 2018 to 2019 for MLSPZV3 and from 2019 to 2021 for MLSPZV4, with follow-up during malaria seasons across 2 years. In MLSPZV3, 478 adults were assessed for eligibility, of whom 220 were enrolled between May 30 and June 12, 2018, and then between Aug 13 and Aug 18, 2018, and 210 received dose one. 66 (96%) of 69 participants who received the 16-week schedule and 68 (97%) of 70 who received the 4-week schedule of the 9 × 105 PfSPZ Vaccine and 70 (99%) of 71 who received saline completed all three doses in year 1. In MLSPZV4, 407 women were assessed for eligibility, of whom 324 were enrolled from July 3 to July 27, 2019, and 320 received dose one of presumptive artemether-lumefantrine. 300 women were randomly assigned with 100 per group (PfSPZ Vaccine 9 × 105, 1·8 × 106, or saline) receiving dose one. First trimester miscarriages were the most commonly reported serious adverse event but occurred at a similar rate across study groups (eight [15%] of 54 with 9 × 105 PfSPZ Vaccine, 12 [21%] of 58 with 1·8 × 106 PfSPZ Vaccine, and five [12%] of 43 with saline). One unrelated maternal death occurred 425 days after the last vaccine dose in the 1·8 × 106 PfSPZ Vaccine group due to peritonitis shortly after childbirth. Most related adverse events reported in MLSPZV3 and MLSPZV4 were mild (grade 1) and frequency of adverse events in the PfSPZ Vaccine groups did not differ from that in the saline group. Two unrelated serious adverse events occurred in MLSPZV3 (one participant had appendicitis in the 9 × 105 PfSPZ Vaccine group and the other in the saline group died due to a road traffic accident). In MLSPZV3, the 9 × 105 PfSPZ Vaccine did not show vaccine efficacy against parasitaemia with the 4-week (27% [95% CI -18 to 55] in year 1 and 42% [-5 to 68] in year 2) and 16-week schedules (16% [-34 to 48] in year 1 and -14% [-95 to 33] in year 2); efficacies were similar or worse against clinical malaria compared with saline. In MLSPZV4, the PfSPZ Vaccine showed significant efficacy against parasitaemia at doses 9 × 105 (41% [15 to 59]; p=0·0069 in year 1 and 61% [36 to 77]; p=0·0011 in year 2) and 1·8 × 106 (54% [34 to 69]; p<0·0001 in year 1 and 45% [13 to 65]; p=0·029 in year 2); and against clinical malaria at doses 9 × 105 (47% [20 to 65]; p=0·0045 in year 1 and 56% [22 to 75]; p=0·0081 in year 2) and 1·8 × 106 (48% [22 to 65]; p=0·0013 in year 1 and 40% [2 to 64]; p=0·069 in year 2). Vaccine efficacy against post-conception P falciparum parasitaemia during first pregnancies that arose in the 2-year follow-up was 57% (14 to 78; p=0·017) in the 9 × 105 PfSPZ Vaccine group versus 49% (3 to 73; p=0·042) in the 1·8 × 106 PfSPZ Vaccine group. Among 55 women who became pregnant within 24 weeks after dose three, vaccine efficacy against parasitaemia was 65% (23 to 84; p=0·0088) with the 9 × 105 PfSPZ Vaccine and 86% (64 to 94; p<0·0001) with the 1·8 × 106 PfSPZ Vaccine. When combined in a post-hoc analysis, women in the PfSPZ Vaccine groups had a non-significantly reduced time-to-first pregnancy after dose one compared with those in the saline group (log-rank test p=0·056). Exploratory maternal obstetric and neonatal outcomes did not differ significantly between vaccine groups and saline. INTERPRETATION: PfSPZ Vaccine was safe and well tolerated in adults in Mali. The 9 × 105 and 1·8 × 106 doses of PfSPZ Vaccine administered as per the 4-week schedule, which incorporated presumptive antimalarial treatment before the first vaccine dose, showed significant efficacy against P falciparum parasitaemia and clinical malaria for two malaria transmission seasons in women of childbearing age and against pregnancy malaria. PfSPZ Vaccine without presumptive antimalarial treatment before the first vaccine dose did not show efficacy. FUNDING: National Institute of Allergy and Infectious Diseases, National Institutes of Health, and Sanaria.
引用
- Diawara H, Healy SA, Mwakingwe-Omari A, et al. Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis. 2024. PMID: 39153490. doi:10.1016/S1473-3099(24)00360-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。